We report the results from a study of the full sample of 66.03110 super(7) K super(c)1p super(c) p super(0) p super(0) decays recorded by the NA48/2 experiment at the CERN SPS. As first observed in ...this experiment, the p super(0) p super(0) invariant mass (M sub(00)) distribution shows a cusp-like anomaly in the region around M sub(00)=2m sub(+), where m sub(+) is the charged pion mass. This anomaly has been interpreted as an effect due mainly to the final state charge exchange scattering process p super(+) p super(-)1p super(0) p super(0) in K super(c)1p super(c) p super(+) p super(-) decay. Fits to the M sub(00) distribution using two different theoretical formulations provide the presently most precise determination of a sub(0)-a sub(2), the difference between the p p S-wave scattering lengths in the isospin I=0 and I=2 states. Higher-order p p rescattering terms, included in the two formulations, allow also an independent, though less precise, determination of a sub(2).
This paper deals with wide area monitoring with Phasor Measurement Units (PMU). It shows the principles and possible applications and points to further trends. An example for an advanced User ...Interface is given which helps the operator in interpreting the Phasor Measurement Data. An application example in a German Transmission System Operator's surrounding is described.
(ProQuest: ... denotes formulae and/or non-USASCII text omitted; see image) Abstract A sample of 65210 K ^sup ±^ arrow right pi ^sup 0^ pi ^sup 0^ e ^sup ±^ nu (K^sub e4^^sup 00^) decay candidates ...with 1% background contamination has been collected in 2003-2004 by the NA48/2 collaboration at the CERN SPS. A study of the differential rate provides the first measurement of the hadronic form factor variation in the plane (M ^sub ππ^^sup 2^,M ^sub enu^^sup 2^) and brings evidence for a cusp-like structure in the distribution of the squared pi ^sup 0^ pi ^sup 0^ invariant mass around ... Exploiting a model independent description of this form factor, the branching ratio, inclusive of radiative decays, is obtained using the K ^sup ±^ arrow right pi ^sup 0^ pi ^sup 0^ pi ^sup ±^ decay mode as normalization. It is measured to be BR(K^sub e4^^sup 00^) = (2.552 ± 0.010^sub stat^ ± 0.010^sub syst^ ± 0.032^sub ext^) × 10^sup -5^, which improves the current world average precision by an order of magnitude while the 1.4% relative precision is dominated by the external uncertainty from the normalization mode. A comparison with the properties of the corresponding mode involving a pi ^sup +^ pi ^sup -^ pair (K^sub e4^^sup +-^) is also presented.
The NA48/2 experiment at CERN reports the first observation of the \(K^{\pm} \rightarrow \pi^{0} \pi^{0} \mu^{\pm} \nu\) decay based on a sample of 2437 candidates with 15% background contamination ...collected in 2003--2004. The decay branching ratio in the kinematic region of the squared dilepton mass above \(0.03\)~GeV\(^2/c^4\) is measured to be \((0.65 \pm 0.03) \times 10^{-6}\). The extrapolation to the full kinematic space, using a specific model, is found to be \((3.45 \pm 0.16) \times 10^{-6}\), in agreement with chiral perturbation theory predictions.
Abstract
Background
Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies ...confirm that pGluAB42 is a particular amyloid form that is highly synaptotoxic and plays a significant role in the development of AD.
Methods
This paper describes the design and methodology behind the phase 2b VIVIAD-trial in AD. The aim of this study is to evaluate varoglutamstat in a state-of-the-art designed, placebo-controlled, double-blind, randomized clinical trial for safety and tolerability, efficacy on cognition, and effects on brain activity and AD biomarkers. In addition to its main purpose, the trial will explore potential associations between novel and established biomarkers and their individual and composite relation to disease characteristics.
Results
To be expected early 2023
Conclusion
This state of the art phase 2b study will yield important results for the field with respect to trial methodology and for the treatment of AD with a small molecule directed against pyroglutamate-A-beta.
Trial registration
ClinicalTrials.gov Identifier:
NCT04498650
In an integrative approach, we studied the role of histamine H
receptors in the mouse heart. We noted that histamine, added cumulatively to the organ bath, failed to affect the force of contraction ...in left atrial preparations and did not change spontaneous heart rate in right atrial preparations from wild-type mice. By contrast, in the same preparations from mice that overexpressed the human H
receptor in a cardiac-specific way, histamine exerted concentration- and time-dependent positive inotropic and positive chronotropic effects. Messenger RNA of the human H
receptor was only detected in transgenic mice. Likewise, immunohistology and autoradiography only gave signals in transgenic but not in wild-type cardiac preparations. Similarly, a positive inotropic and positive chronotropic effect was observed with histamine in echocardiography of living transgenic mice and isolated perfused hearts (Langendorff preparation). Phosphorylation of phospholamban was increased in atrial and ventricular preparations from transgenic mice, but not in wild-type animals. The effects of histamine were mimicked by dimaprit and amthamine and antagonized by cimetidine. In summary, we generated a new model to study the physiologic and pathophysiologic cardiac role of the human H
receptor.
PDF
